Novocure Ltd Ord Sh (NVCR)

Apr 1, 2025, 7:00 AM EDT - 3 days ago

Novocure to Report First Quarter 2025 Financial Results

Mar 4, 2025, 7:00 AM EST - 4 weeks ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

Feb 28, 2025, 1:10 PM EST - 5 weeks ago

NovoCure Q4 2024 Earnings: Strong And Growing Pipeline

Feb 28, 2025, 5:17 AM EST - 5 weeks ago

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth

Feb 27, 2025, 9:09 AM EST - 5 weeks ago

NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript

Feb 27, 2025, 7:00 AM EST - 5 weeks ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Jan 22, 2025, 4:00 AM EST - 2 months ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Jan 13, 2025, 7:00 AM EST - 2 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Jan 3, 2025, 7:00 AM EST - 3 months ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 9:59 PM EST - 4 months ago

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Dec 2, 2024, 1:10 PM EST - 4 months ago

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Dec 2, 2024, 10:12 AM EST - 4 months ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Dec 2, 2024, 7:17 AM EST - 4 months ago

Novocure's pancreatic cancer treatment meets main goal in late-stage study

Dec 2, 2024, 7:02 AM EST - 4 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

ZLAB

Dec 2, 2024, 7:00 AM EST - 4 months ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Nov 27, 2024, 7:00 AM EST - 4 months ago

Novocure to Participate in Upcoming Investor Conferences

Nov 21, 2024, 7:05 AM EST - 4 months ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Nov 21, 2024, 7:00 AM EST - 4 months ago

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Oct 30, 2024, 11:53 AM EDT - 5 months ago

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

Oct 30, 2024, 7:02 AM EDT - 5 months ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Oct 30, 2024, 7:00 AM EDT - 5 months ago

Novocure Reports Third Quarter 2024 Financial Results

Oct 16, 2024, 11:00 AM EDT - 6 months ago

NovoCure: There Is Still More Upside

Oct 16, 2024, 7:28 AM EDT - 6 months ago

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

Oct 15, 2024, 4:43 PM EDT - 6 months ago

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Oct 1, 2024, 7:00 AM EDT - 6 months ago

Novocure to Report Third Quarter 2024 Financial Results

Sep 9, 2024, 7:00 AM EDT - 7 months ago

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Sep 3, 2024, 7:00 AM EDT - 7 months ago

Novocure Announces Planned CEO Transition

Aug 28, 2024, 7:00 AM EDT - 7 months ago

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

Aug 14, 2024, 7:00 AM EDT - 8 months ago

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Aug 12, 2024, 5:13 PM EDT - 8 months ago

Biotech stocks: Which drugmakers are worth a buy?

ARGX

Jul 26, 2024, 12:34 PM EDT - 9 months ago

NovoCure Limited: A Post Q2 Analysis

Jul 25, 2024, 12:35 PM EDT - 9 months ago

NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript

Jul 25, 2024, 7:00 AM EDT - 9 months ago

Novocure Reports Second Quarter 2024 Financial Results

Jul 1, 2024, 7:00 AM EDT - 9 months ago

Novocure to Report Second Quarter 2024 Financial Results

Jun 3, 2024, 8:00 AM EDT - 10 months ago

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

May 23, 2024, 5:05 PM EDT - 11 months ago

TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany

May 2, 2024, 7:01 AM EDT - 1 year ago

Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon

May 2, 2024, 7:00 AM EDT - 1 year ago

Novocure Reports First Quarter 2024 Financial Results

Apr 24, 2024, 10:45 AM EDT - 1 year ago

Results of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

Apr 1, 2024, 7:00 AM EDT - 1 year ago

Novocure to Report First Quarter 2024 Financial Results

Mar 27, 2024, 2:26 PM EDT - 1 year ago

Novocure's stock surges after positive results in brain-cancer trial

Mar 27, 2024, 9:29 AM EDT - 1 year ago

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

ZLAB

Mar 27, 2024, 7:12 AM EDT - 1 year ago

Novocure's lung cancer therapy succeeds in late-stage trial

Mar 27, 2024, 7:00 AM EDT - 1 year ago

METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO

Feb 22, 2024, 10:50 AM EST - 1 year ago

NovoCure Limited (NVCR) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 7:00 AM EST - 1 year ago

Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Jan 18, 2024, 7:00 AM EST - 1 year ago

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Jan 9, 2024, 7:00 AM EST - 1 year ago

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma